The Medicaid best price rule is an elegant policy mechanism with an unintended consequence that has become inseparable from its intended effect. Under the Medicaid Drug Rebate Program, manufacturers that want their drugs covered by Medicaid must agree to charge the program no more than the lowest price they charge any other payer — the “best price” — after accounting for all discounts, rebates, and other price concessions. The logic was protective: the largest public payer in the country should not be disadvantaged relative to commercial buyers with greater negotiating sophistication. The effect has been to create a pricing floor that constrains how aggressively manufacturers can negotiate with commercial payers, because any concession offered commercially flows through to Medicaid.
The Chilling Effect on Commercial Negotiation
A manufacturer considering a fifty-percent discount to a large commercial payer must calculate not just the commercial revenue impact but the Medicaid revenue impact, because the discount would trigger a best price reset that applies to the entire Medicaid market. For drugs with substantial Medicaid utilization, the aggregate revenue implication of a commercial best price concession may exceed the value of the commercial contract being negotiated. Manufacturers facing this calculus often decline aggressive commercial discounts, preferring to maintain list price discipline that protects their Medicaid revenue floor. The best price rule thus generates a cross-market subsidy in which commercial negotiating leverage is effectively capped by the Medicaid exposure of the manufacturer’s product.
The policy has generated a series of workarounds that illustrate the creativity that regulatory constraints inspire in sophisticated commercial actors. Manufacturers have structured innovative payment arrangements — outcomes-based contracts, indication-specific pricing, lease arrangements for certain cell and gene therapies — that are designed to fall outside the best price calculation, allowing more aggressive commercial discounting without triggering the Medicaid floor. CMS has repeatedly had to issue guidance on which arrangements qualify for best price exclusion and which do not, producing a regulatory cat-and-mouse dynamic that absorbs substantial compliance resources on both sides and still generates uncertainty at the margin.
Indication-Specific Pricing and Its Limits
The indication-specific pricing workaround deserves particular attention because it has attracted substantial policy interest as a potential mechanism for value-based drug pricing at scale. Several oncology drugs are used across multiple indications — cancers — with meaningfully different efficacy profiles and thus different defensible price points. A manufacturer that could price a drug at different levels for different indications would be able to align price with value and offer more aggressive discounts for lower-value indications without affecting the best price for higher-value uses. CMS has acknowledged the conceptual validity of indication-specific pricing but has not established a regulatory framework that operationalizes it at scale in the fee-for-service Medicaid context, where claims data does not always support reliable indication identification.
The downstream effect of the best price rule on formulary design is also underappreciated. Plans and PBMs that might otherwise negotiate aggressively — demanding deep discounts as a condition of formulary preference — face a manufacturer counterparty whose willingness to discount is constrained by Medicaid exposure. In therapeutic categories with high Medicaid utilization, the negotiating dynamic is fundamentally different from categories where Medicaid plays a minor role. The result is a segmented commercial negotiating environment where the same manufacturer may be willing to discount aggressively in one category and resist in another, for reasons that have nothing to do with the clinical or competitive merits of the commercial negotiation.
Reform Proposals and Their Tensions
Reform proposals for the best price rule typically fall into two categories: eliminating it (allowing manufacturers to discount commercially without Medicaid consequences, on the theory that competitive negotiation will produce better net prices), or restructuring it to accommodate value-based arrangements and indication-specific pricing without destroying the program’s cost protection function. Both approaches carry real risks. Eliminating best price protections for Medicaid would require a compelling theory of why commercial market competition would produce prices favorable to Medicaid, a market with different payer dynamics and patient populations. Restructuring the rule to allow more commercial flexibility risks creating loopholes that manufacturers exploit to narrow the effective best price calculation without genuine commercial discounting. The best price rule is a constraint on commercial markets that is genuinely difficult to relax without consequences for the public program it was designed to protect. That is not an argument for preserving it unchanged; it is an argument for taking its second-order effects as seriously as the reform advocates tend to take its first-order inefficiencies.
